ASTRAZENECA PLC (ZEG.DE) Stock Fundamental Analysis
Europe - FRA:ZEG - GB0009895292 - Common Stock
153.3 EUR
+0.55 (+0.36%)
ZEG gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 54 industry peers in the Pharmaceuticals industry. While ZEG has a great profitability rating, there are quite some concerns on its financial health. While showing a medium growth rate, ZEG is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
In the past year ZEG was profitable.
ZEG had a positive operating cash flow in the past year.
Each year in the past 5 years ZEG has been profitable.
In the past 5 years ZEG always reported a positive cash flow from operatings.
1.2 Ratios
ZEG has a better Return On Assets (8.21%) than 64.81% of its industry peers.
With a decent Return On Equity value of 20.48%, ZEG is doing good in the industry, outperforming 68.52% of the companies in the same industry.
ZEG's Return On Invested Capital of 14.42% is fine compared to the rest of the industry. ZEG outperforms 72.22% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for ZEG is below the industry average of 14.51%.
The 3 year average ROIC (11.62%) for ZEG is below the current ROIC(14.42%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.21% | ||
| ROE | 20.48% | ||
| ROIC | 14.42% |
ROA(3y)5.35%
ROA(5y)4.19%
ROE(3y)13.78%
ROE(5y)12.42%
ROIC(3y)11.62%
ROIC(5y)9.52%
1.3 Margins
ZEG has a better Profit Margin (16.17%) than 66.67% of its industry peers.
In the last couple of years the Profit Margin of ZEG has grown nicely.
With a decent Operating Margin value of 24.34%, ZEG is doing good in the industry, outperforming 62.96% of the companies in the same industry.
In the last couple of years the Operating Margin of ZEG has grown nicely.
ZEG has a better Gross Margin (81.90%) than 83.33% of its industry peers.
In the last couple of years the Gross Margin of ZEG has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 24.34% | ||
| PM (TTM) | 16.17% | ||
| GM | 81.9% |
OM growth 3Y21.43%
OM growth 5Y8.6%
PM growth 3Y251.6%
PM growth 5Y18.9%
GM growth 3Y3.31%
GM growth 5Y0.47%
2. Health
2.1 Basic Checks
ZEG has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
The number of shares outstanding for ZEG remains at a similar level compared to 1 year ago.
Compared to 5 years ago, ZEG has more shares outstanding
The debt/assets ratio for ZEG is higher compared to a year ago.
2.2 Solvency
ZEG has an Altman-Z score of 5.84. This indicates that ZEG is financially healthy and has little risk of bankruptcy at the moment.
ZEG has a Altman-Z score of 5.84. This is amongst the best in the industry. ZEG outperforms 81.48% of its industry peers.
The Debt to FCF ratio of ZEG is 3.41, which is a good value as it means it would take ZEG, 3.41 years of fcf income to pay off all of its debts.
ZEG has a Debt to FCF ratio of 3.41. This is comparable to the rest of the industry: ZEG outperforms 57.41% of its industry peers.
ZEG has a Debt/Equity ratio of 0.61. This is a neutral value indicating ZEG is somewhat dependend on debt financing.
ZEG has a Debt to Equity ratio of 0.61. This is comparable to the rest of the industry: ZEG outperforms 48.15% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.61 | ||
| Debt/FCF | 3.41 | ||
| Altman-Z | 5.84 |
ROIC/WACC1.6
WACC9%
2.3 Liquidity
ZEG has a Current Ratio of 0.88. This is a bad value and indicates that ZEG is not financially healthy enough and could expect problems in meeting its short term obligations.
ZEG has a Current ratio of 0.88. This is amonst the worse of the industry: ZEG underperforms 81.48% of its industry peers.
ZEG has a Quick Ratio of 0.88. This is a bad value and indicates that ZEG is not financially healthy enough and could expect problems in meeting its short term obligations.
ZEG's Quick ratio of 0.69 is on the low side compared to the rest of the industry. ZEG is outperformed by 77.78% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.88 | ||
| Quick Ratio | 0.69 |
3. Growth
3.1 Past
ZEG shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 4.89%.
Measured over the past years, ZEG shows a quite strong growth in Earnings Per Share. The EPS has been growing by 18.59% on average per year.
ZEG shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 13.52%.
ZEG shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 17.27% yearly.
EPS 1Y (TTM)4.89%
EPS 3Y15.85%
EPS 5Y18.59%
EPS Q2Q%-42.79%
Revenue 1Y (TTM)13.52%
Revenue growth 3Y13.06%
Revenue growth 5Y17.27%
Sales Q2Q%11.99%
3.2 Future
Based on estimates for the next years, ZEG will show a quite strong growth in Earnings Per Share. The EPS will grow by 12.73% on average per year.
The Revenue is expected to grow by 7.18% on average over the next years.
EPS Next Y13.8%
EPS Next 2Y13.64%
EPS Next 3Y12.91%
EPS Next 5Y12.73%
Revenue Next Year9.58%
Revenue Next 2Y7.79%
Revenue Next 3Y7.12%
Revenue Next 5Y7.18%
3.3 Evolution
Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 22.48, the valuation of ZEG can be described as rather expensive.
ZEG's Price/Earnings ratio is in line with the industry average.
When comparing the Price/Earnings ratio of ZEG to the average of the S&P500 Index (25.89), we can say ZEG is valued inline with the index average.
The Price/Forward Earnings ratio is 16.84, which indicates a correct valuation of ZEG.
ZEG's Price/Forward Earnings ratio is in line with the industry average.
When comparing the Price/Forward Earnings ratio of ZEG to the average of the S&P500 Index (34.59), we can say ZEG is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 22.48 | ||
| Fwd PE | 16.84 |
4.2 Price Multiples
64.81% of the companies in the same industry are cheaper than ZEG, based on the Enterprise Value to EBITDA ratio.
64.81% of the companies in the same industry are cheaper than ZEG, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 57.87 | ||
| EV/EBITDA | 27.83 |
4.3 Compensation for Growth
ZEG's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
The decent profitability rating of ZEG may justify a higher PE ratio.
A more expensive valuation may be justified as ZEG's earnings are expected to grow with 12.91% in the coming years.
PEG (NY)1.63
PEG (5Y)1.21
EPS Next 2Y13.64%
EPS Next 3Y12.91%
5. Dividend
5.1 Amount
With a Yearly Dividend Yield of 1.81%, ZEG has a reasonable but not impressive dividend return.
ZEG's Dividend Yield is comparable with the industry average which is at 3.01.
Compared to the average S&P500 Dividend Yield of 2.44, ZEG is paying slightly less dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.81% |
5.2 History
The dividend of ZEG has a limited annual growth rate of 1.40%.
Dividend Growth(5Y)1.4%
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
52.89% of the earnings are spent on dividend by ZEG. This is a bit on the high side, but may be sustainable.
The dividend of ZEG is growing, but earnings are growing more, so the dividend growth is sustainable.
DP52.89%
EPS Next 2Y13.64%
EPS Next 3Y12.91%
FRA:ZEG (11/14/2025, 7:00:00 PM)
153.3
+0.55 (+0.36%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners48.98%
Inst Owner ChangeN/A
Ins Owners0.04%
Ins Owner ChangeN/A
Market Cap475.31B
Revenue(TTM)58.13B
Net Income(TTM)9.40B
Analysts82.42
Price Target156.15 (1.86%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.81% |
Yearly Dividend2.56
Dividend Growth(5Y)1.4%
DP52.89%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-25.51%
Min EPS beat(2)-49.27%
Max EPS beat(2)-1.74%
EPS beat(4)1
Avg EPS beat(4)-10.58%
Min EPS beat(4)-49.27%
Max EPS beat(4)9.32%
EPS beat(8)3
Avg EPS beat(8)-5.46%
EPS beat(12)7
Avg EPS beat(12)-1.7%
EPS beat(16)11
Avg EPS beat(16)0.58%
Revenue beat(2)0
Avg Revenue beat(2)-0.23%
Min Revenue beat(2)-0.24%
Max Revenue beat(2)-0.22%
Revenue beat(4)1
Avg Revenue beat(4)-0.43%
Min Revenue beat(4)-3.99%
Max Revenue beat(4)2.7%
Revenue beat(8)3
Avg Revenue beat(8)0.08%
Revenue beat(12)4
Avg Revenue beat(12)-0.52%
Revenue beat(16)6
Avg Revenue beat(16)0.18%
PT rev (1m)0.82%
PT rev (3m)-0.13%
EPS NQ rev (1m)-1.05%
EPS NQ rev (3m)-0.73%
EPS NY rev (1m)0.05%
EPS NY rev (3m)1.17%
Revenue NQ rev (1m)-0.04%
Revenue NQ rev (3m)-0.26%
Revenue NY rev (1m)-0.04%
Revenue NY rev (3m)0.89%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 22.48 | ||
| Fwd PE | 16.84 | ||
| P/S | 9.52 | ||
| P/FCF | 57.87 | ||
| P/OCF | 36.57 | ||
| P/B | 12.07 | ||
| P/tB | N/A | ||
| EV/EBITDA | 27.83 |
EPS(TTM)6.82
EY4.45%
EPS(NY)9.1
Fwd EY5.94%
FCF(TTM)2.65
FCFY1.73%
OCF(TTM)4.19
OCFY2.73%
SpS16.09
BVpS12.71
TBVpS-3.74
PEG (NY)1.63
PEG (5Y)1.21
Graham Number44.16
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.21% | ||
| ROE | 20.48% | ||
| ROCE | 17.6% | ||
| ROIC | 14.42% | ||
| ROICexc | 16.02% | ||
| ROICexgc | 81.56% | ||
| OM | 24.34% | ||
| PM (TTM) | 16.17% | ||
| GM | 81.9% | ||
| FCFM | 16.46% |
ROA(3y)5.35%
ROA(5y)4.19%
ROE(3y)13.78%
ROE(5y)12.42%
ROIC(3y)11.62%
ROIC(5y)9.52%
ROICexc(3y)12.66%
ROICexc(5y)10.55%
ROICexgc(3y)112.76%
ROICexgc(5y)85.06%
ROCE(3y)13.95%
ROCE(5y)11.45%
ROICexgc growth 3Y43.28%
ROICexgc growth 5Y4.77%
ROICexc growth 3Y41%
ROICexc growth 5Y11.99%
OM growth 3Y21.43%
OM growth 5Y8.6%
PM growth 3Y251.6%
PM growth 5Y18.9%
GM growth 3Y3.31%
GM growth 5Y0.47%
F-Score7
Asset Turnover0.51
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.61 | ||
| Debt/FCF | 3.41 | ||
| Debt/EBITDA | 1.34 | ||
| Cap/Depr | 84.97% | ||
| Cap/Sales | 9.59% | ||
| Interest Coverage | 10.83 | ||
| Cash Conversion | 73.11% | ||
| Profit Quality | 101.79% | ||
| Current Ratio | 0.88 | ||
| Quick Ratio | 0.69 | ||
| Altman-Z | 5.84 |
F-Score7
WACC9%
ROIC/WACC1.6
Cap/Depr(3y)61.87%
Cap/Depr(5y)60.41%
Cap/Sales(3y)7.51%
Cap/Sales(5y)7.64%
Profit Quality(3y)144.6%
Profit Quality(5y)772.45%
High Growth Momentum
Growth
EPS 1Y (TTM)4.89%
EPS 3Y15.85%
EPS 5Y18.59%
EPS Q2Q%-42.79%
EPS Next Y13.8%
EPS Next 2Y13.64%
EPS Next 3Y12.91%
EPS Next 5Y12.73%
Revenue 1Y (TTM)13.52%
Revenue growth 3Y13.06%
Revenue growth 5Y17.27%
Sales Q2Q%11.99%
Revenue Next Year9.58%
Revenue Next 2Y7.79%
Revenue Next 3Y7.12%
Revenue Next 5Y7.18%
EBIT growth 1Y26.07%
EBIT growth 3Y37.28%
EBIT growth 5Y27.35%
EBIT Next Year34.36%
EBIT Next 3Y17.49%
EBIT Next 5Y13.09%
FCF growth 1Y37.12%
FCF growth 3Y24.58%
FCF growth 5Y70.22%
OCF growth 1Y46.1%
OCF growth 3Y25.76%
OCF growth 5Y31.92%
ASTRAZENECA PLC / ZEG.DE FAQ
What is the fundamental rating for ZEG stock?
ChartMill assigns a fundamental rating of 5 / 10 to ZEG.DE.
What is the valuation status for ZEG stock?
ChartMill assigns a valuation rating of 3 / 10 to ASTRAZENECA PLC (ZEG.DE). This can be considered as Overvalued.
What is the profitability of ZEG stock?
ASTRAZENECA PLC (ZEG.DE) has a profitability rating of 7 / 10.
Can you provide the PE and PB ratios for ZEG stock?
The Price/Earnings (PE) ratio for ASTRAZENECA PLC (ZEG.DE) is 22.48 and the Price/Book (PB) ratio is 12.07.
Can you provide the financial health for ZEG stock?
The financial health rating of ASTRAZENECA PLC (ZEG.DE) is 3 / 10.